Van Leeuwen R - Search Results

1

Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.

Stilianakis NI, Boucher CA, De Jong MD, Van Leeuwen R, Schuurman R, De Boer RJ. Stilianakis NI, et al. Among authors: van leeuwen r. J Virol. 1997 Jan;71(1):161-8. doi: 10.1128/JVI.71.1.161-168.1997. J Virol. 1997. PMID: 8985335 Free PMC article.

2

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, Keulen W, de Groot T, Boucher CA. Nijhuis M, et al. Among authors: van leeuwen r. J Infect Dis. 1997 Aug;176(2):398-405. doi: 10.1086/514056. J Infect Dis. 1997. PMID: 9237704

3

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, et al. Schuurman R, et al. Among authors: van leeuwen r. J Infect Dis. 1995 Jun;171(6):1411-9. doi: 10.1093/infdis/171.6.1411. J Infect Dis. 1995. PMID: 7539472

4

Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.

Boucher CA, van Leeuwen R, Kellam P, Schipper P, Tijnagel J, Lange JM, Larder BA. Boucher CA, et al. Among authors: van leeuwen r. Antimicrob Agents Chemother. 1993 Jul;37(7):1525-30. doi: 10.1128/AAC.37.7.1525. Antimicrob Agents Chemother. 1993. PMID: 8103317 Free PMC article.

5

Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.

van 't Wout AB, Ran LJ, Nijhuis M, Tijnagel JM, de Groot T, van Leeuwen R, Boucher CA, Schuitemaker H, Schuurman R. van 't Wout AB, et al. Among authors: van leeuwen r. AIDS. 1998 Jul 9;12(10):1169-76. doi: 10.1097/00002030-199810000-00009. AIDS. 1998. PMID: 9677166

6

Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.

van Leeuwen R, Lange JM, Nijhuis M, Schuurman R, Reiss P, Danner SA, Boucher CA. van Leeuwen R, et al. Antivir Ther. 1997 Apr;2(2):79-90. Antivir Ther. 1997. PMID: 11322279

7

Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Schuurman R, Descamps D, Weverling GJ, Kaye S, Tijnagel J, Williams I, van Leeuwen R, Tedder R, Boucher CA, Brun-Vezinet F, Loveday C. Schuurman R, et al. Among authors: van leeuwen r. J Clin Microbiol. 1996 Dec;34(12):3016-22. doi: 10.1128/jcm.34.12.3016-3022.1996. J Clin Microbiol. 1996. PMID: 8940441 Free PMC article. Clinical Trial.

8

Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.

van't Wout AB, Ran LJ, de Jong MD, Bakker M, van Leeuwen R, Notermans DW, Loeliger AE, de Wolf F, Danner SA, Reiss P, Boucher CA, Lange JM, Schuitemaker H. van't Wout AB, et al. Among authors: van leeuwen r. J Clin Invest. 1997 Nov 1;100(9):2325-32. doi: 10.1172/JCI119771. J Clin Invest. 1997. PMID: 9410911 Free PMC article.

9

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.

van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. van Leeuwen R, et al. J Infect Dis. 1995 May;171(5):1166-71. doi: 10.1093/infdis/171.5.1166. J Infect Dis. 1995. PMID: 7751691 Clinical Trial.

10

Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.

Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, Lange JM, Miedema F, Danner SA, Schellekens PT. Pakker NG, et al. Among authors: van leeuwen r. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 15;16(5):318-26. doi: 10.1097/00042560-199712150-00002. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9420308

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

404 results

Search Page

Filters